Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > What's positive about no news? Shareholders want to know.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(199)
•••
Post by Red~Oneon Jan 17, 2022 7:19pm
217 Views
Post# 34326524

What's positive about no news? Shareholders want to know.

What's positive about no news? Shareholders want to know.Summary of today's news:

Salzman and Bob are lining up again. Choosing from the endless list of genuine possible treatments that could use R107 and Bob keeps paying it out to the Claritas Team in shares....... Think about it....... It's like your own ATM. ....Just line up...... Make room for more shares...... In one of the last "Updates" there was an obvious hint that Bob doesn't have enough cash to finish Phase 1...... There was another referance to an old Barda grant for over $15 Mill .....was that the same $15.9  million US dollars that the other team got for their postponed work with R107 and CILI ?.....Where's the good news....oh would that be Phase 1? Was the start announced...... Is it even booked?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities